$599

Novo Semaglutide MASH Data; Abbott GLP-1RA Adherence Study; Alnylam and Regeneron Q3 ’24 Earnings

A series of cardiometabolic-related news items have been observed from Novo Nordisk, Abbott, Alnylam, and Regeneron. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here